STOCK TITAN

Neuronetics, Inc. - STIM STOCK NEWS

Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.

Neuronetics, Inc. (NASDAQ: STIM) is a pioneering medical technology company renowned for its NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation (TMS) to treat psychiatric and neurological disorders. Headquartered in Malvern, PA, Neuronetics has established itself as a leading force in the non-invasive treatment of major depressive disorder (MDD), particularly for patients who have not found relief from standard antidepressant medications.

The company's flagship product, the NeuroStar Advanced Therapy System, is FDA-cleared for the treatment of MDD in adults and approved for additional indications, including obsessive-compulsive disorder (OCD) and anxious depression in patients exhibiting comorbid anxiety symptoms. Notably, NeuroStar recently received FDA clearance to treat adolescents aged 15-21, making it the first TMS therapy to be approved for this age group. This expanded clearance has significantly increased Neuronetics' market potential, addressing an underserved segment of the population.

Neuronetics continues to make strides in both product development and market reach. The recent advancements in their TrakStar® Patient Data Management System have enhanced the way healthcare providers manage and document patient treatment, improving workflow and patient outcomes. Furthermore, the company has forged strategic partnerships, such as the five-year exclusive agreement with Transformations Care Network, facilitating greater access to NeuroStar TMS across multiple states.

The company's commitment to enhancing mental health treatment accessibility is evident through its proactive health policy advocacy. Neuronetics is the only TMS company with a dedicated health policy team, actively working with providers and payors to update coverage criteria. This effort has yielded favorable changes in insurance coverage, making TMS therapy more accessible to those in need.

Financially, Neuronetics has shown promising growth. In the fourth quarter of 2023, the company reported a 12% increase in total revenue, driven primarily by an uptick in NeuroStar treatment session sales. The gross margin improved to 77.6%, bolstered by strong revenue growth and efficient expense management. The company's strategic initiatives, including the Better Me Guarantee Provider Program, aim to further enhance patient care and treatment accessibility. With a robust pipeline of projects and ongoing financial improvements, Neuronetics is well-positioned for sustained growth and innovation in the mental health sector.

Rhea-AI Summary

MALVERN, Pa., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Neuronetics, a medical technology company, will release its third quarter financial results on November 9, 2021, before market open. A conference call to discuss these results is scheduled for 8:30 a.m. ET that day, available via webcast on ir.neuronetics.com. Participants can dial in using (877) 472-8990 for U.S. callers or +1 (629) 228-0778 for international callers, referencing code 3891687. The call will be recorded and available for replay for 60 days. Neuronetics focuses on products that enhance the quality of life for neurohealth patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
none
-
Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) announced preliminary third-quarter revenue of approximately $13.8 million, falling short of previous guidance of $15.0 million to $16.0 million. The company now expects full-year revenue between $53.3 million and $54.3 million. The lower revenue was attributed to a new sales team's delayed productivity due to extended sales cycles linked to the ongoing Covid-19 situation. Despite this, the company is making progress on strategic initiatives, including a successful NeuroStar Summit and ongoing discussions with the FDA for potential label expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.69%
Tags
none
Rhea-AI Summary

Neuronetics (NASDAQ: STIM) reported preliminary revenues for Q3 2021, expecting approximately $13.8 million, lower than previously estimated guidance of $15.0 million to $16.0 million. Full-year revenue is forecasted to be between $53.3 million and $54.3 million. CEO Keith J. Sullivan attributed the shortfall to the new sales team's productivity challenges amid extended sales cycles influenced by the Covid-19 pandemic. Despite this, the company made progress on strategic initiatives, including successful marketing campaigns and productive discussions with the FDA regarding potential label expansions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.53%
Tags
none
-
Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) has entered an exclusive five-year commercial agreement with Success TMS, which will utilize Neuronetics’ NeuroStar Advanced Therapy exclusively to treat patients with treatment-resistant major depressive disorder (MDD). Additionally, Neuronetics has made a strategic investment of $10 million to support Success TMS's growth. Success TMS aims to triple its size in the next two years, having provided over 250,000 treatments across 30 sites in six states. This partnership emphasizes the commitment to improving patient access to non-drug therapies for neurohealth disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
-
Rhea-AI Summary

Neuronetics, a medical technology company focused on neurohealth, has announced new partnerships with mental health advocates for National Depression Education and Awareness Month. The company’s NeuroStar® Therapy leads the non-invasive treatment for depression. The campaign, featuring Dr. Melissa Shepard, aims to educate patients and physicians on this breakthrough technology. Additionally, NeuroStar is sponsoring key events to raise awareness and promote mental health research. With over four million treatments delivered, NeuroStar remains committed to transforming lives through effective non-drug therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
Rhea-AI Summary

Neuronetics (NASDAQ: STIM) has partnered with Zion Healing to become the exclusive supplier of TMS equipment for Zion's mental health clinics. This agreement aims to enhance patient access to NeuroStar® Advanced Therapy, a non-invasive treatment for depression. Robert Beatty, CEO of Zion Healing, emphasized the urgent need for mental health services, while Neuronetics' President, Keith J. Sullivan, highlighted the partnership's potential to expand treatment availability. NeuroStar has delivered over 4 million treatments, demonstrating its efficacy in adult patients with major depressive disorder.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.05%
Tags
none
-
Rhea-AI Summary

Neuronetics, Inc. (NASDAQ: STIM) announced the launch of an enhanced website aimed at improving the user experience for patients seeking information on advanced depression treatments. Market research reveals that 67% of Major Depressive Disorder patients are dissatisfied with current treatments. The new site provides essential resources, including a physician locator tool and success stories, to empower patients and healthcare providers. With rising depression rates post-COVID-19, this initiative underscores Neuronetics' commitment to addressing unmet mental health needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.31%
Tags
none
-
Rhea-AI Summary

Neuronetics (NASDAQ: STIM) has appointed Megan Rosengarten to its Board of Directors, expanding the board to eight members. Rosengarten brings over two decades of experience in medical technology, currently serving as President of Surgical Robotics at Medtronic. She previously held roles at Hologic, Covidien, and Johnson & Johnson. Her expertise in product development and marketing is expected to enhance Neuronetics' growth strategy for its NeuroStar Advanced Therapy for Mental Health, which is FDA-cleared for treating major depressive disorder. The company aims to increase awareness and adoption of this innovative therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
management
Rhea-AI Summary

Neuronetics, a medical technology company, reported a 46% revenue increase to $14.2 million for Q2 2021, driven by a 65% rise in U.S. treatment session revenue. The company highlighted 83% response and 62% remission rates from its NeuroStar Outcomes Registry. While gross margin improved to 80.6%, operating expenses rose to $18 million. A net loss of $(7.5) million was reported, slightly better than the previous year's $(7.8) million. For full-year 2021, revenue is projected between $59 million and $63 million, with Q3 expectations between $15 million and $16 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.98%
Tags
none

FAQ

What is the current stock price of Neuronetics (STIM)?

The current stock price of Neuronetics (STIM) is $1.46 as of December 24, 2024.

What is the market cap of Neuronetics (STIM)?

The market cap of Neuronetics (STIM) is approximately 94.9M.

What does Neuronetics, Inc. specialize in?

Neuronetics specializes in developing non-invasive therapies for psychiatric and neurological disorders using transcranial magnetic stimulation (TMS).

What is the NeuroStar Advanced Therapy System?

The NeuroStar Advanced Therapy System is a non-invasive and non-systemic treatment that uses transcranial magnetic stimulations to treat major depressive disorder (MDD) and other neurohealth conditions.

Is NeuroStar therapy FDA-approved?

Yes, NeuroStar therapy is FDA-cleared for adults with major depressive disorder (MDD) and has recently been approved for use in adolescents aged 15-21.

How does NeuroStar therapy work?

NeuroStar therapy uses MRI-strength magnetic field pulses to stimulate specific areas of the brain associated with mood, providing a non-invasive alternative to traditional antidepressants.

What recent advancements has Neuronetics made?

Recent advancements include the FDA clearance for treating adolescents with MDD, enhancements to the TrakStar® Patient Data Management System, and strategic partnerships to expand NeuroStar's availability.

How is Neuronetics improving access to mental health treatments?

Neuronetics is improving access through proactive health policy advocacy, resulting in favorable insurance coverage changes, and strategic partnerships with major mental health care providers.

What is the Better Me Guarantee Provider Program?

The Better Me Guarantee Provider Program is an initiative by Neuronetics to ensure high standards of patient care and responsiveness, aiming to enhance treatment accessibility and patient outcomes.

How has Neuronetics performed financially?

Neuronetics has shown financial growth with a 12% increase in revenue in Q4 2023 and improved gross margins, driven by increased utilization of NeuroStar treatment sessions.

What is the company's approach to mental health?

Neuronetics believes mental health is as important as physical health and is committed to offering non-drug, non-invasive treatments that improve the quality of life for those with neurohealth conditions.

How can I contact Neuronetics for support?

For support, you can email customer support at customersupport@neuronetics.com or call (877) 600-7555 for U.S. inquiries and +1 (610) 640-4207 for international customers.

Neuronetics, Inc.

Nasdaq:STIM

STIM Rankings

STIM Stock Data

94.90M
27.28M
11.1%
53.32%
2.43%
Diagnostics & Research
Surgical & Medical Instruments & Apparatus
Link
United States of America
MALVERN